Bradley Sitko has been our Chief Investment Officer since January 2023. Mr. Sitko served as Managing Director, Strategic Finance, at RTW Investments, LP, a global, full life-cycle investment firm in the biopharmaceutical and medical technology sectors from November 2019 to January 2023 where he led the royalty monetization, structured finance and alternatives efforts of the firm. He also served as a member of the Board of such firm’s Irish collective asset-management vehicle (ICAV), RTW Investments ICAV. During that same time, he was Chief Financial Officer of Ji Xing Pharmaceuticals Limited, a Shanghai-based biopharmaceutical company, incubated by RTW Investments, LP with responsibilities involving company formation, scaling operations, fundraising, and in-licensing of biotech assets. From March 2015 to November 2019, Mr. Sitko served as Vice President, Finance, Operations and Corporate Development of DNAnexus, Inc., a genetic data management company with responsibilities involving restructuring and recapitalization, fundraising, finance and operations, strategic planning and industry partnerships. Mr. Sitko also served as a Director at MTS Health Partners, an investment bank, from October 2008 to March 2015, where he advised on royalty monetization, financing, restructurings, and mergers and acquisitions within the biopharmaceutical and healthcare services sectors. Mr. Sitko received a B.A. in History and Sociology of Science from the University of Pennsylvania and an M.B.A. from Columbia Business School.
What is Bradley Sitko's net worth?
The estimated net worth of Bradley Sitko is at least $157.05 thousand as of April 7th, 2025. Mr. Sitko owns 5,045 shares of XOMA Royalty stock worth more than $157,051 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Sitko may own. Learn More about Bradley Sitko's net worth.
How do I contact Bradley Sitko?
Has Bradley Sitko been buying or selling shares of XOMA Royalty?
Bradley Sitko has not been actively trading shares of XOMA Royalty during the last quarter. Most recently, on Monday, April 7th, Bradley Sitko bought 2,000 shares of XOMA Royalty stock. The stock was acquired at an average cost of $24.70 per share, with a total value of $49,400.00. Following the completion of the transaction, the executive now directly owns 5,045 shares of the company's stock, valued at $124,611.50. Learn More on Bradley Sitko's trading history.
Who are XOMA Royalty's active insiders?
Are insiders buying or selling shares of XOMA Royalty?
In the last year, XOMA Royalty insiders bought shares 6 times. They purchased a total of 29,925 shares worth more than $750,844.26. In the last year, insiders at the biotechnology company sold shares 4 times. They sold a total of 923,432 shares worth more than $24,518,663.26. The most recent insider tranaction occured on September, 22nd when CFO Thomas M Burns sold 4,330 shares worth more than $155,836.70. Insiders at XOMA Royalty own 9.1% of the company.
Learn More about insider trades at XOMA Royalty. Information on this page was last updated on 9/22/2025.
